News from PTC Therapeutics, Celgene and Heron Therapeutics
This content is for members
PTC Therapeutics (PTCT)
Highlighting Gene Editing Firms
This content is for members
Observing Queer Stories
This content is for members
In the Limelight
This content is for members
The Year in Review Part 2
This content is for members
New Possible Treatment for Glioblastoma, Why PTCT Stock Rallied on Bad News and More
This content is for members
Calming Down PTC Therapeutics Investors’ Concerns. More Good News from Sangamo. AERIE’s Glaucoma Drug NDA
This content is for members
Prohost Letter #401
This content is for members
PTC Therapeutics Stock Price Doubles. When the Data Are Not Good for Forecasting.
This content is for members
Prohost Letter #396
This content is for members
Exelixis Again. The Road to Defeating DMD. Two New Important IPOs
EXELIXIS AGAIN They said: Sell EXEL, as no partner is interested in the firm’s FDA approved cabozantinib to date. What really happened: It did not take long …
Good News Does Not Always Mean Good Investment Opportunities
This content is for members
Prohost Letter #388
This content is for members
Prohost Letter #387
This content is for members
PTC Therapeutics: Results of DMD Trial Are Good for Approval
This content is for members
More Successes Achieved in the Gene-Editing Group
This content is for members